Cormedix Inc CRMD

$7.30 +0.11 (1.53%)

Valuation

Market cap
560,417,000
Revenue TTM
$311,710,000
Net income TTM
$163,060,000
PE ratio
3.91
Forward PE
13.74
Profit margin
52.31%
Debt to equity
0.00

Trading

Volume
838,269
Avg volume
1,115,848
Day's range
$7.06 – $7.33
Shares out
77,944,000
Stochastic %K
2%
Beta
1.40
Analysts
Strong Sell
Price target
$14.25

Price

Company profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company,...

Show more

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
908 517 9500
Website
https://cormedix.com
Address
389 Interpace Pkwy, Suite 450, Parsippany, United States

Latest news